Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Mattsson

Showing results (151-160 of 258) with videos related to

Pageof 26
Sort By:
Transplantation and Cellular Therapy|January 12, 2026
Clinical Impact of HHV-6B Reactivation on Engraftment and Outcomes Following Allogeneic Hematopoietic Stem Cell TransplantationSeyed M Hosseini-Moghaddam, Rochelle B Johnstone, Tony Mazzulli, et al.
European Journal of Haematology|July 20, 2024
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experienceNihar Desai, Ivan Pasic, Arjun D Law, et al.
Bone Marrow Transplantation|February 24, 2024
Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host diseaseAlistair Murray, Swe Mar Linn, Benoit Yu, et al.
Acta Haematologica|May 20, 2020
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeWael Alanazi, Shiyi Chen, Jeffrey H Lipton, et al.
Cancer Research|April 2, 2021
Mesothelin-Specific CAR T Cells Target Ovarian CancerEsther Schoutrop, Ibrahim El-Serafi, Thomas Poiret, et al.
American Journal of Hematology|October 27, 2020
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely optionAhmad S Alotaibi, Shruti Prem, Shiyi Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2012
Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host diseaseOlle Ringdén, Mats Remberger, Katarina Holmberg, et al.
Annals of Hematology|March 12, 2021
Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantationArjun Datt Law, Sita Bhella, Ivan Pasic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2019
Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host DiseaseRoman M Shapiro, Elizabeth Shin, Arjun Datt Law, et al.
European Journal of Haematology|September 13, 2019
Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosisMaria Queralt Salas, Wilson Lam, Arjun Datt Law, et al.
Pageof 26

Showing results (151-160 of 258) with videos related to

Sort By:
Pageof 26
Transplantation and Cellular Therapy|January 12, 2026
Clinical Impact of HHV-6B Reactivation on Engraftment and Outcomes Following Allogeneic Hematopoietic Stem Cell TransplantationSeyed M Hosseini-Moghaddam, Rochelle B Johnstone, Tony Mazzulli, et al.
European Journal of Haematology|July 20, 2024
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experienceNihar Desai, Ivan Pasic, Arjun D Law, et al.
Bone Marrow Transplantation|February 24, 2024
Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host diseaseAlistair Murray, Swe Mar Linn, Benoit Yu, et al.
Acta Haematologica|May 20, 2020
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeWael Alanazi, Shiyi Chen, Jeffrey H Lipton, et al.
Cancer Research|April 2, 2021
Mesothelin-Specific CAR T Cells Target Ovarian CancerEsther Schoutrop, Ibrahim El-Serafi, Thomas Poiret, et al.
American Journal of Hematology|October 27, 2020
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely optionAhmad S Alotaibi, Shruti Prem, Shiyi Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2012
Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host diseaseOlle Ringdén, Mats Remberger, Katarina Holmberg, et al.
Annals of Hematology|March 12, 2021
Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantationArjun Datt Law, Sita Bhella, Ivan Pasic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2019
Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host DiseaseRoman M Shapiro, Elizabeth Shin, Arjun Datt Law, et al.
European Journal of Haematology|September 13, 2019
Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosisMaria Queralt Salas, Wilson Lam, Arjun Datt Law, et al.
Pageof 26